Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects.

Trial Profile

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2010

At a glance

  • Drugs APD 916 (Primary)
  • Indications Cataplexy; Narcolepsy
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Oct 2010 Status changed from recruiting to completed.
    • 21 Oct 2010 Results reported in a Arena Pharmaceuticals media release.
    • 27 Mar 2010 Official title, lead investigator added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top